NCT05470998View on ClinicalTrials.gov

L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

PHASE3RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Sickle Cell Disease

Interventions

DRUG

L-Arginine

L-Arginine 1000 mg free form, rapid release capsules

Trial Locations (1)

Unknown

RECRUITING

Tanta university, Tanta

All Listed Sponsors

lead

Tanta University

OTHER